Associate Professor | Senior Research Officer
07 3845 3725dylan.glubb@qimrberghofer.edu.au
After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into antidepressant pharmacogenomics at the University of Otago. Afterwards, he continued working at the University of Otago as a Research Fellow, studying the biological function of genes involved with inflammatory bowel disease. Dylan moved to the United States in 2009 to perform postdoctoral training, researching the functional genetics of the VEGF-pathway and its relationship with cancer at the University of Chicago and, subsequently, the University of North Carolina, Chapel Hill.
In 2013, Dylan began working at QIMR Berghofer and has undertaken the functional follow-up of large-scale genetic studies of breast, endometrial and ovarian cancer to identify the likely causal variants and genes that mediate associations with cancer risk and survival.
Click the link to view Dylans cv: link
2019-present: Senior Research Officer, Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute
2019-present: Adjunct Associate Professor, Faculty of Health, Queensland University of Technology
2019-present: Honorary Associate Professor, Faculty of Medicine, University of Queensland
2017-2019: Visiting Fellow, Faculty of Health, Queensland University of Technology
2013-2019: Research Officer, Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute
2011-2013: Postdoctoral Research Associate, School of Pharmacy, University of North Carolina
2009-2011: Postdoctoral Research Scholar, Department of Medicine, University of Chicago
2008-2009: Research Fellow, Department of Pathology, University of Otago
View Dylan’s Google Scholar Publications here
Dylan’s research interests include functional genetic and genomic studies of disease and follow-up of genome-wide association studies to identify target genes underlying genetic associations. Currently, his main research efforts are focussed on ovarian and endometrial cancer. As a member of the international Endometrial Cancer Association Consortium, he is leading functional genomic studies to identify target genes from the largest GWAS of endometrial cancer performed to date (O’Mara, Glubb et al. Nature Communications, 2018) and GWAS meta-analysis of ovarian and endometrial cancer (Glubb, et al. Cancer Epidemiology, Prevention and Biomarkers, 2020). These analyses will inform the aetiology of gynaecological cancers and have identified new candidates for drug targeting. Dylan is exploring the targeting of these candidates using artificial intelligence approaches to prioritise compounds for further study.
2020: External reviewer, Swiss National Science Foundation
2020: Guest editor, Cancers
2018-present: Editorial board member, PLoS One
2018-present: Scientific member, Endometrial Tumour Type Working Group (Australia New Zealand Gynaecological Group)
2018-2019: Active member, American Association for Cancer Research
2017-2018: External grant reviewer, NHMRC
2016-present: Member, Endometrial Cancer Association Consortium
2015-present: Member, Australia New Zealand Gynaecological Group
2014-present: Member, American Society of Human Genetics
2019-2020: Principal Investigator, QIMR Berghofer Proof of Concept Award ($18,154)
2019-2020: CIB, NHMR Project grant ($179,763)
2019: Atomwise Artificial Intelligence Molecular Screen Awards (three molecular screens awarded)
2018: American Society of Human Genetics Reviewer’s Choice Award
2018: The Bridge Residential Training Program Travel Bursary
2018: Principal Investigator, QIMR Berghofer NHMR Near Miss Funding ($50,000)
2017: Australia New Zealand Gynaecological Oncology Group Travel Award
2017: Principal Investigator, QIMR Berghofer NHMR Near Miss Funding ($30,000)
2016: CASS Foundation Travel Award
2016: American Society of Human Genetics Reviewer’s Choice Award
2015-2017: Consultant, National Cancer Institute R21 Grant ($384,475)
2014: Finalist, American Society of Human Genetics/Charles J. Epstein Award for Excellence in Human Genetics Research
2014: American Society of Human Genetics Travel Award for best Australian trainee abstract
2009: PhD, Pharmacogenomics, University of Otago
1999: MSc (First Class Hons), Cellular & Molecular Biology, University of Canterbury
1997: BSc, Biochemistry and Plant & Microbial Sciences, University of Canterbury